Alphatec (NASDAQ:ATEC) Hits New 1-Year High - Should You Buy?

Key Points

• Alphatec Holdings, Inc. reached a new **52-week high** of $13.89, with significant trading volume of **12,995,953 shares**.
• Brokerages reaffirmed a **"buy" rating** for the stock, with price targets ranging from **$15.00 to $20.00**, reflecting strong growth expectations.
• The company reported a **22.2% increase in revenue** year-over-year, though it missed earnings estimates with an EPS of **($0.35)** for the latest quarter.

Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC - Get Free Report) reached a new 52-week high on Saturday . The stock traded as high as $13.89 and last traded at $13.77, with a volume of 12995953 shares trading hands. The stock had previously closed at $10.58.

Analysts Set New Price Targets

ATEC has been the subject of several recent analyst reports. HC Wainwright restated a "buy" rating and issued a $20.00 target price on shares of Alphatec in a research note on Monday, April 14th. Piper Sandler reiterated an "overweight" rating and set a $15.00 price objective (up previously from $13.00) on shares of Alphatec in a research report on Friday, May 2nd. Needham & Company LLC reiterated a "buy" rating and set a $16.00 price objective on shares of Alphatec in a research report on Friday, May 2nd. Barclays lifted their price target on Alphatec from $21.00 to $22.00 and gave the company an "overweight" rating in a report on Monday. Finally, Canaccord Genuity Group reaffirmed a "buy" rating and issued a $20.00 price objective on shares of Alphatec in a research note on Friday. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $18.50.

Alphatec Stock Performance

The firm has a market cap of $2.20 billion, a price-to-earnings ratio of -13.16 and a beta of 1.05. The stock has a fifty day moving average price of $11.41 and a 200 day moving average price of $11.18. The company has a current ratio of 2.88, a quick ratio of 1.77 and a debt-to-equity ratio of 23.22.

Alphatec (NASDAQ:ATEC - Get Free Report) last posted its earnings results on Thursday, July 31st. The medical technology company reported $0.02 EPS for the quarter, topping the consensus estimate of ($0.06) by $0.08. The business had revenue of $185.54 million during the quarter, compared to the consensus estimate of $178.85 million. Alphatec had a negative return on equity of 1,657.19% and a negative net margin of 24.33%. Alphatec's revenue was up 27.5% on a year-over-year basis. During the same quarter last year, the company earned ($0.29) EPS. As a group, analysts predict that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current year.

Insider Activity

In other Alphatec news, COO Scott Lish sold 3,982 shares of the firm's stock in a transaction on Thursday, July 10th. The stock was sold at an average price of $12.00, for a total transaction of $47,784.00. Following the transaction, the chief operating officer owned 744,936 shares in the company, valued at $8,939,232. This trade represents a 0.53% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Craig E. Hunsaker sold 13,878 shares of Alphatec stock in a transaction on Thursday, June 5th. The shares were sold at an average price of $12.36, for a total value of $171,532.08. Following the completion of the transaction, the executive vice president owned 1,450,018 shares in the company, valued at approximately $17,922,222.48. The trade was a 0.95% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 287,547 shares of company stock worth $3,553,516 over the last three months. Corporate insiders own 22.80% of the company's stock.

Institutional Trading of Alphatec

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. GAMMA Investing LLC increased its holdings in shares of Alphatec by 38,433.3% in the first quarter. GAMMA Investing LLC now owns 2,312 shares of the medical technology company's stock worth $228,000 after purchasing an additional 2,306 shares during the period. Comerica Bank boosted its position in Alphatec by 66.8% during the fourth quarter. Comerica Bank now owns 3,116 shares of the medical technology company's stock valued at $29,000 after buying an additional 1,248 shares during the period. Larson Financial Group LLC purchased a new stake in Alphatec during the first quarter valued at about $54,000. Quarry LP boosted its position in Alphatec by 79.2% during the fourth quarter. Quarry LP now owns 5,374 shares of the medical technology company's stock valued at $49,000 after buying an additional 2,375 shares during the period. Finally, Nisa Investment Advisors LLC boosted its position in Alphatec by 22.4% during the second quarter. Nisa Investment Advisors LLC now owns 5,714 shares of the medical technology company's stock valued at $63,000 after buying an additional 1,045 shares during the period. 66.35% of the stock is owned by institutional investors.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.